News

404

Study Shows IP-001 to Amplify Tumoricidal and Immune Effect of Cancer Ablation Therapies

Study Shows IP-001 to Amplify Tumoricidal and Immune Effect of Cancer Ablation Therapies

A paper recently published in Cells has described how Immunophotonics’ immune-stimulating drug IP-001 was shown to be effective against metastatic tumors when combined with different forms tumor ablation. In this review, the authors briefly discuss the current applications of local ablation for cancer treatment and the effects of IP-001 in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO). The full text of the article may be downloaded here: https://www.mdpi.com/2073-4409/10/3/492#cite

Scroll to top